For example, when combined with poly(I:C) and other adjuvants, Clec9a-fused antigens induce CD4- and CD8-mediated anti-tumor immunity (147, 148), while fusion of human IFNα to Cle9a led to an anti-tumor response that was improved by treatment with checkpoint blockade in the murine 4T1 mammary tumor model (149). Here, CD8A is linked to breast cancer.